Skip to main content

Tenpoint aims to make vision loss reversible

| News

Tenpoint aims to make vision loss reversible


The startup Tenpoint Therapeutics has started operations with a funding round of 70 million US dollars. It works to make vision loss reversible at its locations in London and Allschwil.

Tenpoint Therapeutics has developed a platform that can be used to replace cells damaged with age or disease. This technology aims to make vision loss reversible. The startup established in London with operational headquarters in Allschwil at the Switzerland Innovation Park Basel Area has now announced in a press release that it will start operations with a series A round of financing amounting to 70 million US dollars. Basel Area Business & Innovation supported Tenpoint with its settlement in Allschwil  in the canton of Basel-Landschaft.

The biotech company will now develop cell-based therapies and perform in-vivo cell reprogramming. This makes healthy cells available to replace cells that can no longer function. Tenpoint’s CEO Eddy Anglade stated in the press release that most cases of vision loss are due to damaged or missing tissue, adding that this is why “cell-based therapeutics represent an ideal modality for degenerative ocular diseases.” Tenpoint focuses on addressing the causes of vision loss.

All seed investors that had previously enabled the company to be set up were involved in the funding round. Additionally, a new investor was brought on board in the form of British Patient Capital. Chair of the Board David Guyer commented: “Tenpoint has great potential to lead ophthalmology into a new era, which will fully replace cells lost to degenerative conditions rather than merely endeavoring to slow the processes that drive vision loss.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.